Motivation: Genetic and gene expression variations within and between populations and across geographical regions have substantial effects on the biological phenotypes, diseases, and therapeutic response. The development of precision medicines can be facilitated by the OMICS studies of the patients of specific ethnicity and geographic region. However, there is an inadequate facility for broadly and conveniently accessing the ethnic and regional specific OMICS data.
Introduction
Significant genetic and gene expression variations have been observed between different ethnic groups of the human populations, which lead to the population differences in the prevalence of complex diseases and drug responses (Spielman et al., 2007; Stranger et al., 2007; Zhang et al., 2008; O'Donnell and Dolan, 2009; Roden and George, 2002) . Substantial genetic and gene expression variations have also been found within specific ethnic groups, between different genders and across different age groups, which result in the within-population, between-gender or across-age groups in disease susceptibilities and drug responses (Cantuti-Castelvetri et al., 2007; Trabzuni et al., 2013; Chow et al., 2012; Reynolds et al., 2014; Li et al., 2010; Roden and George, 2002) . Moreover, genetic and gene expression variations can also be induced by the geographical, environmental and social factors (e.g. socioeconomic status and urbanity level) and by food intakes that also vary across different geographical regions (Idaghdour et al., 2008; Tabassum et al., 2013; Cole, 2013; Cole, 2014; Leonardson et al., 2010; Micha et al., 2015) .
Given the fact that genetic and gene expression variations strongly influence the diseases, disease susceptibilities and drug responses, there have been intensive efforts and call for more extensive consideration of patients' specific personal traits (such as ethnicity, gender, age and region of residence) in the investigations of their diseases progressions and mechanisms, and in the research and development of the precision and stratified therapeutics and diagnosis (Bonham et al., 2016; Liu et al., 2016; O'Donnell and Dolan, 2009; Tan et al., 2016; Wissing et al., 2014; Regitz-Zagrosek, 2006; Chow et al., 2012; Vavala et al., 2017) . These efforts may be facilitated by the convenient access of the genomic and gene expression data of diverse groups of patients with well-annotated personal traits.
A number of popular databases have been developed to collectively provide the genetic and gene expression data of diverse groups of patients of large variety of diseases, these databases include the Gene Expression Omnibus (GEO), ArrayExpress, The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) (Barrett et al., 2013; Cancer Genome Atlas Research et al., 2013; Grossman et al., 2016; Kolesnikov et al., 2015; Zhang et al., 2011) . Moreover, several specialized databases provide convenient access of the ethnic specific genomic data. In particular, 1000 Genomes Project provides the largest public catalogue of human variation and genotype data of 2500 patients from 26 ethnic populations (The 1000 Genomes Project Consortium et al., 2015) . FINDbase contains comprehensive information about clinically relevant genomic variation allele frequencies of different ethnic groups (Papadopoulos et al., 2014) , NEMDB includes ethnic mutation data of different population groups (Patrinos, 2006) , ALFRED provides allele frequencies in different populations (Rajeevan et al., 2012) , VCGDB stores the dynamic genome data of the Chinese population (Ling et al., 2014) , KGVDB gives a population-based genomic map of CNVs tagged by SNPs in Koreans (Moon et al., 2013) and SGVP contains the single nucleotide polymorphisms data of the Chinese, Malay and Indian populations in Southeast Asia (Teo et al., 2009) .
However, few databases have been developed for convenient access of the ethnic or population specific gene expression data of individual patients. While the information about geographic region and/ or ethnic population of the individual patients is contained in a substantial portion (27.2% based on our data mining analysis) of the gene expression entries of the human samples in the popular databases, there is a lack of facility for supporting the search of the relevant data by user-specified personal traits, and the information of the personal traits in the entries of these databases cannot be easily extracted without manual inspection or using data-mining methods. There are two databases that support data search by user-specified personal traits, one is the most recently launched NIH National Cancer Institute Genomic Data Commons Data Portal (Grossman et al., 2016) which provides an integrated portal to access multidimensional omics data of samples from the Cancer Genome Atlas (TCGA) and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) program, the other is the HGV database hosted by the Human Genome Variation (an online open access journal, access at https://hgv.figshare.com). However, the coverage of these two databases (14 353 patients of 33 cancer types and 149 patients of 59 disease conditions, respectively) is rather limited compared to those in the combined entries of the aforementioned major databases that contain some personal traits information (53 070 patients and 169 disease conditions based on our data-mining analysis).
Hence, there is a need for a user-friendly facility or resource that supports the convenient access of the genetic and gene expression data of more diverse groups of patients and more variety of diseases by user-specified personal traits as well as diseases. To cater this need, we introduced a new database, HEROD, a human ethnic and regional specific omics database, with initial focus on the collection of the most comprehensive sets of gene expression data with available personal traits information, and on the introduction of a userfriendly search facility to support the convenient access of these data by more refined classes of the personal traits and more diverse ranges diseases than those provided by the two existing databases (Grossman et al., 2016) . Specifically, the more refined classes of personal traits including the ethnic populations classified based on 1000 genomes population categories, and more specific geographic region such as a particular city or province or state. Besides the personal traits of patients, we extracted and standardized a wide range of clinical metadata, such as disease stage, biomarker mutation status and other pathological properties.
In view that the International Classification of Diseases (ICD) codes have been widely adopted by >110 countries and used by physicians, researchers, policy-makers and insurers for defining and studying diseases, monitoring and managing health care, and allocating resources (Bramer, 1988; Wood, 1990) , the works by these healthcare professionals and researchers in the research, management and regulation of precision medicine and personalized healthcare may be facilitated by the access of the genetic and gene expression data of the patients via the ICD codes. We therefore introduced into HEROD the ICD code search option. Moreover, to assist the analysis of the relevant patient data with respect to the related biological studies, and tool development and evaluation efforts, we also introduced into HEROD the search options by sample source organs, sample types and assay types. We also added a World map search option to enable the users to access the relevant data by clicking a specific nation of residence. Users can access and download the gene expression data and well-organized clinical metadata of a specific patient group defined by one or multiple search options.
Materials and methods

Geographic region and ethnicity annotation
Firstly, all datasets in GEO or ArrayExpress were analyzed to select those datasets that contain human samples. Since GEO and ArrayExpress typically share data with each other, we only collected a dataset from GEO when it is deposited in both databases. The study title and study description text of each dataset was extracted from the databases and subjected to keywords (e.g. 'human', 'homo sapiens', 'patient', 'disease' and 'tissue') matching using data mining programming scripts. Then, the selected datasets/studies were manually checked to remove those studies that only include samples from cultured human cell lines, animal models and cultured human primary cells. This is to ensure that only those studies of human tissue/ blood samples were selected for subsequent analysis.
Secondly, the referenced publications of selected studies were manually evaluated to extract geographic region (and/or ethnicity when available) information. A challenge of annotating ethnicity or the geographic region information is that these information are not explicitly noted but rather contained in the respective references. Therefore, manual inspection of the relevant publications is necessary to accurately extract and evaluate the collected information. Although the GEO and ArrayExpress database provide the contact address (institute, city and country) of the corresponding authors of each study, in most cases, this contact address is not the geographic location where patients were recruited. Therefore, we manually read all the referenced publications to find the geographic region information from such sections as the 'Methods and Materials' section and the supplementary materials. The geographic region of the patients was divided into three classes: location of sample collection (the hospital or institute that recruit patients and collect samples), city of sample collection (the city of sample collection or the hospital/institute belongs to) and geographic region (the country/ region of sample collection or the hospital/institute belongs to). For instance, in the GSE65216 (a study ID assigned by GEO database) study, the region information of the studied patients was described at the 'Materials and methods' section of the corresponding publication (reference PubMed ID: 23700430) as follows: 'We obtained 154 tumor samples (DNA, RNA and biopsies) from patients treated at the hospital of Institut Curie (Biological Resource Center, Paris, France)'. Therefore, we extracted the region information at three levels: (i) Location of Sample Collection: hospital of Institut Curie; (ii) City of Sample Collection: Paris; (iii) Geographic Region: France.
Ethnicity/race information of majority patients was mainly mined from plain texts from GEO or ArrayExpress database. Besides, ethnicity information was also collected from publications when these information was only available in publication but did not be presented in deposited databases. For entries from TCGA or ICGC, clinical metadata (including the region and ethnicity information) of patients was directly extracted from each database, when either geographic region or ethnicity/race information is available. After annotating the geographic region and ethnicity information, patients were tentatively categorized into seven super ethnic population groups (African, American, European, East Asian, West Asian, South Asian and Oceanian), based on the 1000 genomes classification system. The patients that cannot be assigned into these population groups were labeled as 'NA'. Besides, the detailed ethnicity/race information (e.g. White, Black, Chinese and Malay) is also labeled when available.
Gene expression data collection
After annotating the geographic region and/or ethnic population of the selected patients, we downloaded the gene expression files of the samples of each patient. Only those annotated patients that have available gene expression files were finally recorded in the HEROD database. The flowchart of HEROD data collection and processing processes is illustrated in Figure 1. 
Clinical metadata standardization
There are a wide range of clinical properties of patients being recorded in GEO and ArrayExpress database. These metadata included: gender, age, disease condition, disease subtype, vitality status (alive/death) and survival data (e.g. overall survival time, disease-free-survival time). For cancer patient entries, we further collected the information about the tumor stage, grade, relapse and metastasis status, the cancer subtypes (e.g. ER, PR, HER2, lymph node and margin status for breast cancers, and MMR, CIMP, CIN and MSI status for colorectal cancer patients), and genetic mutation status (e.g. TP53, KRAS and BRAF mutation status). These clinical metadata carried critical messages useful for data re-exploration. However, there are several challenges in utilizing this precious resource. The first is that, the patient data are typically provided in plain texts without a standard format. The second is that, there is no consistent nomenclature of clinical data categories. To make the HEROD data more useful, many efforts were devoted to extract and standardize these clinical metadata. To collect these clinical metadata, the 'Series Matrix File' or tabdelimited txt files of each study were downloaded from GEO ftp site or ArrayExpress website, respectively. Then aforementioned clinical properties were extracted from these files and formatted with a uniformed style. For example, the status of HER2 in breast cancer may be indicated using 'her2þ', 'þ', 'positive', 'her2 (1 positive 0 negative): 1', or 'her2: 1' in different downloaded files. In the HEROD, 'Positive/Negative' will be used instead of these unformatted symbols to indicate the HER2 status.
We also collected the information about the assay types and omics profiling platforms used for measuring the gene expression data of the donors, the patient type (patient or healthy), sample source organ (e.g. blood or specific organ tissue), and sample type (disease or normal sample). In assigning the ICD code to the diseases of the HEROD entries, the ICD-10 clinical modification ICD-10-CM codes adapted by the United States (Wood, 1990) were used because of their comprehensive coverage of medical conditions. The ICD-10-CM codes were matched to the diseases of the HEROD entries by the following method. Firstly, automated word match was conducted for matching the name of the disease of each HEROD entry with the disease or medical description of each ICD code. Secondly, each of the fully or partially matched HEROD entries was manually checked to validate or correct the matched ICD code. Thirdly, manual evaluation and ICD code matching was conducted for each HEROD entry not matched by step 1 and 2 above. Table 1 shows the statistics of the data analyzed by us and included in HEROD. Overall, a total of 4 004 491 entries and 139 683 studies (including the duplicates) from the four major databases (GEO, ArrayExpress, TCGA and ICGC) were automatically screened to select 389 339 (9.7%) entries (with the duplicates removed) and 5 006 (3.6%) studies with the corresponding gene expression data measured from human samples (excluding cell-lines). The referenced publications of some of these entries and studies were evaluated and the remaining ones will be continuously examined for finding and extracting the information about the personal traits of individual patients. So far, we evaluated 217 834 entries and 1 810 studies (representing 55.9% of the entries and 36.2% of the studies of the human samples) to check the availability of geographical information, ethnicity/race and gene expression raw data. Out of these evaluations, 60 283 entries and 459 studies were found to have geographical information and/or ethnicity and gene expression data available, which account for 27.2% of the entries and 25.4% of the studies of the human samples.
Results
Database contents
Overall, HEROD currently contains the gene expression data of 53 070 patients in seven ethnic population groups from 49 countries and 193 cities and of 169 diseases. Table 1 provides the statistics of the patient data evaluated and included in HEROD. Table 2 contains the list of the top-ranked diseases, geographical region and ethnicity of the HEROD covered gene expression data with > 500 patients. About 86% of HEROD entries were enriched from GEO or ArrayExpress database and large amount of patients have general personal traits (geographic region, ethnicity, age and gender) annotated ( Fig. 2A and B) .
Database access and web interface
As is shown in Figure 3A , HEROD data can be accessed by 14 different search modes. The first mode is the keyword search in the Quick Search field, where a user can search HEROD entries by inputting a disease name (e.g. Breast Cancer), ICD code (e.g. C50, which represents breast cancer), nation or city of residence (e.g. United States, New York) and/or ethnic population (e.g. European, East Asian). The other 12 search modes are in the Advanced Search field. These 12 search modes are (i) disease name, (ii) disease in ICD code, (iii) geographical region, (iv) city of residence, (v) location of sample collection, (vi) ethnic population, (vii) age, (viii) gender, (ix) sample source organ, (x) sample type (Disease/Normal Sample), (xi) assay type and (xii) data source (the database from which the patients' gene expression data was extracted). Users can search with individual mode or combinations of multiple modes by selecting from the dropdown list of an individual menu or those of the multiple menus the specific disease, personal traits, sample source organ, assay type etc. Furthermore, the World Map Search function provides an intuitive way to search patients from specific geographic regions by clicking corresponding regions on the world map.
Searched results will be presented on a new webpage which contains a table showing important information of searched patients, including patient ID, gender, age, region, city, ethnic population, race, disease, disease subtype, ICD 10 code, involved external study of this patient, number of samples from this patient, omics profiling assay type and profiling platform (Fig. 3B) . Moreover, detailed information of each patient can be browsed on another webpage which can be accessed by clicking each patient ID in the search results table (Fig. 3D) . Users can directly download the metadata (includes all detailed information of each patient) and/or gene expression data (raw data files of samples from GEO/ArrayExpress and normalized data files of samples from TCGA/ICGC) of these searched patients using the download buttons (Fig. 3C) . Other detailed user guide and feature instructions can be found from the 'ABOUT' or 'HELP' pages of the web interface.
Discussion
Hundreds of thousands of transcriptomics profiles of human samples under extensive range of pathological conditions have been evaluated and deposited in publically accessible repositories such as GEO, ArrayExpress, TCGA and ICGC. Large-scale re-exploration of these valuable data is gaining more and more attentions and has led to many important findings (Gentles et al., 2015; Kilpinen et al., 2008; Nagalla et al., 2013; Rung and Brazma, 2013; Schmid et al., 2012) . For example, the mRNA expression level transcription factor CDX2 was revealed as a prognostic biomarker of colon cancer by analyzing a combined dataset included 2 329 gene expression arrays of human colon tissues which derived from 28 independent original studies (Dalerba et al., 2016) . Comprehensive maps of human gene expression were generated in (Lukk et al., 2010) and (Torrente et al., 2016) via characterizing combined gene expression dataset included 5 372 and 28 000 human samples, respectively. Reanalyzing 77 840 gene expression arrays of human samples allowed a better elucidation of mechanism of gene expression variations and prediction of gene biological functions (Fehrmann et al., 2015) . Of note, based on our evaluation, about 27% of publically available gene expression data has provided region and/or ethnicity information of patients either in plain text descriptions or in referenced publications. These large-scale ethnic and regional specific gene expression data is of great significance in facilitating the human populationbased transcriptomics studies, provides a special opportunity for understanding gene expression variations within-and/or betweenpopulations using combined large dataset and may uncover new biological insights which could not be found in those individual studies that have relatively small sample size. However, the fact that the paucity of a specific database that provides geographic region and ethnicity of large amount of patients who have available high throughput genomic data hampers the mining of these valuable data. Our present work that annotates the geographic and ethnicity information and format clinical properties of patients provides a solution for this problem and will largely benefit data re-use for analyzing region/ethnicity-specific gene expression patterns or understanding gene expression variations interor intra-populations, which may subsequently benefit patient stratification and precision medicine.
Large-scale annotation of patients' transcriptomics data is of important value for the research community. Beside the annotation of geographic region and ethnic population of patients, we extracted and standardized a wide range of important clinical properties of patients. While HEROD covers comprehensive sets of the gene expression data of 53 070 patients of seven ethnic population groups from 193 cities/ provinces and 49 countries, there remains a significant percentage of the entries in the major databases with the respective publications yet to be manually evaluated for finding the personal traits information for the individual patients in these entries. In the future, continuous efforts will be directed at the manual evaluation of these remaining entries to provide a more comprehensive coverage of the ethnic and regional specific gene expression data in HEROD. Efforts will also be devoted to the extraction of other OMICS data of the patients of specific ethnicity, geographic region and other personal traits, which will be included in HEROD to make it a more useful resource for ethnic and regional specific OMICS data. Based on the manual evaluation studies conducted so far, we notice that a significant percentage (72.8%) of the gene expression entries of the human samples lack personal traits information in the referenced publications. Based on our limited data analyzed so far, there seems to be significantly less numbers of the gene expression data entries with personal traits information in African, South American, Asia and Eastern European nations, and in all non-white ethnic populations, which are disproportionate with the populations in these nations and ethnic groups. Therefore, there is a need for more conscious efforts in recording the personal traits and other important information of the patients under investigations, particularly in the nations and ethnic groups mentioned above.
Although big data is continuing to drive the precision medicine and translational medical researches, there is a great concern about ethical issues of using large bulk of patients' genomic data. The HEROD database mainly focuses on gene expression data, and does not include any DNA sequence and individual germline variant data, avoiding the risk of privacy leakage. All the curated data (e.g. pathological metadata, geographic data and gene expression) is adopted from publically accessible databases or scientific publications. Re-use of the HEROD data is not permitted for any other purpose except for scientific research. 
